Results of the IDEAL trial: "Mirror, mirror on the wall... which's the fairest peginterferon of them all?" - Commentary

Hepatology

Volumn 50, Issue 6, 2009, Pages 2034-2037

  Zur Wiesch, Julian Schulze ^a   Lohse, Ansgar W ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; VIRUS RNA;

CLINICAL TRIAL; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG SAFETY; DRUG TOLERABILITY; ETHNIC DIFFERENCE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; LOW DRUG DOSE; METHODOLOGY; NOTE; OUTCOME ASSESSMENT; PATIENT CARE; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RECURRENCE RISK; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 73149108883     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.23376     Document Type: Note

References (19)

1. Ghany MG, Strader DB, Thomas DL, Seeff LB; American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. HEPATOLOGY 2009;49:1335-1374.
2. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958-965.
3. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Gonçales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002;347:975-982.
4. Sulkowski M, Lawitz E, Shiffman ML, Muir AJ, Galler G, McCone J, et al. Final results of the IDEAL (individualized dosing efficacy versus flat dosing to assess optimal pegylated interferon therapy) phase IIIb study. J Hepatol 2008;48:S370-S371.
5. McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. J Viral Hepat 2008;15:475-481.
6. Dieterich DT. A healthy dose of curiosity: clinical trial results require careful interpretation. Liver Health Today 2008 (January-March).p. 37. Reprinted online at www.natap.org.http://www.natap.org/2008/HCV/c011408-02.htm. Accessed on 04 Nov 2009.
7. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. HEPATOLOGY 2001;34:395-403.
8. Jacobson IM, Brown RS Jr, McCone J, Black M, Albert C, Dragutsky MS, et al. Impact of weight-based ribavirin with peginterferon alfa-2b in African Americans with hepatitis C virus genotype 1. HEPATOLOGY 2007;46: 982-990.
9. Jacobson IM, Brown RS Jr, Freilich B, Afdhal N, Kwo PY, Santoro J, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial. HEPATOLOGY 2007;46:971-981.
10. Maynard M, Pradat P, Gagnieu MC, Souvignet C, Trepo C. Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther 2008;13:607-611.
11. McHutchison JG, Lawitz EJ, Shiffman ML, Muir AJ, Galler GW, Mc-Cone J, et al. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med 2009;361:580-593.
12. Pocock SJ, Ware JH. Translating statistical findings into plain English. Lancet 2009;373:1926-1928.
13. McHutchison JG, Everson GT, Gordon SC, Jacobson IM, Sulkowski M, Kauffman R, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009;360:1827-1838.
14. Hoofnagle JH. A step forward in therapy for hepatitis C. N Engl J Med 2009;360:1899-1901.
15. McGovern BH, Abu Dayyeh BK, Chung RT. Avoiding therapeutic pitfalls: the rational use of specifically targeted agents against hepatitis C infection. HEPATOLOGY 2008;48:1700-1712.
16. McHutchison JG, Dev AT. Future trends in managing hepatitis C. Gastroenterol Clin North Am 2004;33(1 Suppl.):S51-S61.
17. Knight V, Sievert W. When less may not be best-the challenge of individualising antiviral therapy for chronic hepatitis C infection. J Gastroenterol Hepatol 2009;24:330-332.
18. Kawaoka T, Kawakami Y, Tsuji K, Ito H, Kitamoto M, Aimitsu S, et al., Dose comparison study of pegylated interferon-alpha-2b plus ribavirin in naive Japanese patients with hepatitis C virus genotype 2: a randomized clinical trial. J Gastroenterol Hepatol 2009;24:366-371.
19. Ge D, Fellay J, Thompson AJ, Simon JS, Shianna KV, Urban TJ, et al. Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009;421:399-401.